Today, Coloplast is announcing changes to the company’s Executive Leadership Team (ELT). The changes relate to the company’s Interventional Urology business as well as the global People & Culture ...

Ladies and gentlemen, welcome to the Coloplast financial statement for the full year 2024/2025 and Annual Report 2024-2025 Conference Call. I am Sandra, the Chorus Call operator. [Operator ...

The Coloplast Board of Directors are making changes to the Executive Leadership Team (ELT) to support the successful execution of the new Coloplast Group strategy. Over the last couple of months, ...

On Monday, Barclays (LON:BARC) analysts downgraded Coloplast (CSE:COLOb) A/S (COLOB:DC) (OTC: CLPBY) stock rating from Overweight to Equalweight and reduced the price target to DKK750.00 from DKK1,010 ...

(Bloomberg) — Coloplast A/S fired its chief executive officer to restore investor confidence after the medical equipment maker failed to deliver sufficient shareholder returns. That’s according to ...

Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new strategy ...

On Monday, RBC Capital Markets analyst Jack Reynolds-Clark revised the rating for Coloplast (CSE:COLOb) A/S (COLOB:DC) (OTC: CLPBY), elevating it from Sector Perform to Outperform. Accompanying this ...

Coloplast (CSE:COLOb) has been upgraded to an "outperform" rating by RBC Capital Markets, with analysts citing a positive risk-reward balance and a price target increase to DKK 940 per share from DKK ...

On Wednesday, UBS analyst changed the rating for Coloplast (CSE:COLOb) A/S (COLOB:DC) (OTC: CLPBY) from Sell to Neutral, maintaining a price target of DKK858.00. The revision follows a reassessment of ...

Ladies and gentlemen, welcome to the full year 2023-2024 conference call. I am Maria, the Chorus Call operator. I'd like to remind you that all participants will be in listen-only mode. And the ...

Based in Denmark, Coloplast is a leader in global ostomy and continence care. The firm has made inroads into the concentrated urology and fragmented woundcare markets, but it remains a peripheral ...